Table 31Results of the Univariate Sensitivity Analysis Regarding Cost of Relapse

ScenarioResult
Base case62
Cost per mild or moderate relapse =$6,402
Cost per severe relapse = $15,364
If λ < $118,242, glatiramer acetate is a cost-effective treatment.
If $118,242 < λ < $425,655, interferon beta-1b 250 mcg (Extavia) is a cost-effective treatment.
If $425,655 < λ < $872,972, dimethyl fumarate is a cost-effective treatment.
If λ > $872,972, natalizumab is a cost-effective treatment.
Grima et al.74
Cost per relapse = $1,405
If λ < $109,519, glatiramer acetate is a cost-effective treatment.
If $109,519 < λ < $503,474, interferon beta-1b 250 mcg (Extavia) is a cost-effective treatment.
If $503,474 < λ < $913,177, dimethyl fumarate is a cost-effective treatment.
If λ > $913,177, natalizumab is a cost-effective treatment.
Karampampa et al.75
Cost per relapse = $6,402
If λ < $115,694 glatiramer acetate is a cost-effective treatment.
If $115,694 < λ < $448,383, interferon beta-1b 250 mcg (Extavia) is a cost-effective treatment.
If $448,383 < λ < $884,714, dimethyl fumarate is a cost-effective treatment.
If λ>$884,714, natalizumab is cost-effective treatment.
Increase cost of relapse for 100%
Cost per mild or moderate relapse = $12,804
Cost per severe relapse = $30,728
If λ < $128,702, glatiramer acetate is a cost-effective treatment.
If $128,702 < λ < $332,343, interferon beta-1b 250 mcg (Extavia) is a cost-effective treatment;
If $332,343 < λ < $824,762, dimethyl fumarate is a cost-effective treatment.
If λ > $824,762, natalizumab is a cost-effective treatment.

mcg = microgram.

From: 4, RESULTS

Cover of Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis
Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis [Internet].
CADTH Therapeutic Review, No. 1.2B.
Copyright © CADTH March 2013.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.